Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KAT2A | Q92830 | 4/20 | 0.54 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12230839 | 0.86 | CASP3 (0.65) | G6PDGAAKMT2AKAT2AKAT2B | |
| SCHEMBL12205849 | 0.76 | KAT2A (0.58) | G6PDKAT2AKAT2BCASP3CASP7 | |
| SCHEMBL7940591 | 0.75 | GAA (0.46) | GAAMEN1KMT2ASMN1; SMN2CASP3 | |
| SCHEMBL13606221 | 0.75 | G6PD (0.72) | G6PDKAT2AKAT2BCASP3CASP7 | |
| SCHEMBL10027978 | 0.74 | ADRA2C (0.79) | GAAMEN1KMT2ASMN1; SMN2ADRA2C | |
| SCHEMBL23642163 | 0.73 | G6PD (0.82) | G6PDKAT2AKAT2BCASP3CASP7 | |
| SCHEMBL9134025 | 0.73 | KMT2A (0.65) | GAAMEN1KMT2ASMN1; SMN2ADRA2C | |
| SCHEMBL12230840 | 0.73 | KAT2A (0.71) | G6PDKAT2AKAT2BCASP3CASP7 | |
| SCHEMBL13606220 | 0.73 | KAT2A (0.69) | G6PDKAT2AKAT2BCASP3CASP7 | |
| SCHEMBL12230845 | 0.73 | KAT2A (0.70) | G6PDKAT2AKAT2BCASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428472-B2 | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428472-B2 | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9040715-B2 | 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040715-B2 | 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2344479-B1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | UNIV GEORGETOWN (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | GEORGETOWN UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | GEORGETOWN UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2013025897-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | GEORGETOWN UNIVERSITY (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | WICHITA STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | WICHITA STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2010039545-A2 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | GEORGETOWN UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | VIP, VIL1, BAK1 | G6PD 588/4885GAA 1836/4885MEN1 2231/4885 |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | HAVCR2, ERG28, ZC3HAV1 | G6PD 382/4885GAA 1100/4885MEN1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.